Global Generic Drugs Market 2018-2022

About Generic Drugs

A generic drug is a medication created to be the equivalent of an existing approved brand-name drug in terms of dosage form, safety, strength, route of administration, quality, and performance characteristics.

Technavio's analysts forecast the Global Generic Drugs Market to grow at a CAGR of 10.22% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the generic drugs market. To calculate the market size, the report considers the revenue generated from the sales of generic drugs.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, Generic Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• Fresenius Kabi
• Mylan
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries

Market driver

• Rising drug patient expirations
• For a full, detailed list, view our report

Market challenge

• Rising credibility issues
• For a full, detailed list, view our report

Market trend

• Rising M&A
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: MARKET SIZING

• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY APPLICATION

• Anti-infectives
• CNS
• Others

PART 08: MARKET SEGMENTATION BY CATEGORY

• Segmentation by category
• Comparison by category
• Small molecule generics - Market size and forecast 2017-2022
• Biosimilars - Market size and forecast 2017-2022
• Market opportunity by category

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

• Geographical segmentation
• Regional comparison
• Americas - Market size and forecast 2017-2022
• APAC - Market size and forecast 2017-2022
• EMEA - Market size and forecast 2017-2022
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 13: MARKET TRENDS

• Advent of RPA
• Rising M&A
• Hospital-owned generics

PART 14: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Fresenius Kabi
• Mylan
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries

PART 16: APPENDIX

• List of abbreviations

List of Exhibits

• Exhibit 01: Global pharmaceutical market: Market size
• Exhibit 02: Global pharmaceutical market: Segmentation
• Exhibit 03: Market characteristics
• Exhibit 04: Market segments
• Exhibit 05: Market definition - Inclusions and exclusions checklist
• Exhibit 06: Market size 2017
• Exhibit 07: Validation techniques employed for market sizing 2017
• Exhibit 08: Global generic drugs market - Market size and forecast 2017-2022 ($ bn)
• Exhibit 09: Global generic drugs market - Year over year growth 2018-2022 (%)
• Exhibit 10: Five forces analysis 2017
• Exhibit 11: Five forces analysis 2022
• Exhibit 12: Bargaining power of buyers
• Exhibit 13: Bargaining power of suppliers
• Exhibit 14: Threat of new entrants
• Exhibit 15: Threat of substitutes
• Exhibit 16: Threat of rivalry
• Exhibit 17: Market condition - Five forces 2017
• Exhibit 18: Global generic drugs market by category - Market share 2017-2022 (%)
• Exhibit 19: Comparison by category
• Exhibit 20: Global generic drugs market by small molecule generics - Market size and forecast 2017-2022 ($ bn)
• Exhibit 21: Global generic drugs market by small molecule generics - Year over year growth 2018-2022 (%)
• Exhibit 22: Global generic drugs market by biosimilars - Market size and forecast 2017-2022 ($ bn)
• Exhibit 23: Global generic drugs market by biosimilars - Year over year growth 2018-2022 (%)
• Exhibit 24: Market opportunity by category
• Exhibit 25: Customer landscape
• Exhibit 26: Global generic drugs market by region - Market share 2017-2022 (%)
• Exhibit 27: Regional comparison
• Exhibit 28: Generic drugs market in Americas - Market size and forecast 2017-2022 ($ bn)
• Exhibit 29: Generic drugs market in Americas - Year over year growth 2018-2022 (%)
• Exhibit 30: Top three countries in Americas
• Exhibit 31: Generic drugs market in APAC - Market size and forecast 2017-2022 ($ bn)
• Exhibit 32: Generic drugs market in APAC - Year over year growth 2018-2022 (%)
• Exhibit 33: Top three countries in APAC
• Exhibit 34: Generic drugs market in EMEA - Market size and forecast 2017-2022 ($ bn)
• Exhibit 35: Generic drugs market in EMEA - Year over year growth 2018-2022 (%)
• Exhibit 36: Top three countries in EMEA
• Exhibit 37: Market opportunity
• Exhibit 38: Exhibit: Drug patent expirations in 2018
• Exhibit 39: Vendor landscape
• Exhibit 40: Landscape disruption
• Exhibit 41: Vendors covered
• Exhibit 42: Vendor classification
• Exhibit 43: Market positioning of vendors
• Exhibit 44: Fresenius Kabi overview
• Exhibit 45: Fresenius Kabi - Business segments
• Exhibit 46: Fresenius Kabi - Organizational developments
• Exhibit 47: Fresenius Kabi - Geographic focus
• Exhibit 48: Fresenius Kabi - Segment focus
• Exhibit 49: Fresenius Kabi - Key offerings
• Exhibit 50: Mylan overview
• Exhibit 51: Mylan - Business segments
• Exhibit 52: Mylan - Organizational developments
• Exhibit 53: Mylan - Segment focus
• Exhibit 54: Mylan - Key offerings
• Exhibit 55: Novartis overview
• Exhibit 56: Novartis - Business segments
• Exhibit 57: Novartis - Organizational developments
• Exhibit 58: Novartis - Geographic focus
• Exhibit 59: Novartis - Segment focus
• Exhibit 60: Novartis - Key offerings
• Exhibit 61: Pfizer overview
• Exhibit 62: Pfizer - Business segments
• Exhibit 63: Pfizer - Organizational developments
• Exhibit 64: Pfizer - Geographic focus
• Exhibit 65: Pfizer - Segment focus
• Exhibit 66: Pfizer - Key offerings
• Exhibit 67: Sun Pharmaceutical Industries overview
• Exhibit 68: Sun Pharmaceutical Industries - Business segments
• Exhibit 69: Sun Pharmaceutical Industries - Organizational developments
• Exhibit 70: Sun Pharmaceutical Industries - Geographic focus
• Exhibit 71: Sun Pharmaceutical Industries - Segment focus
• Exhibit 72: Sun Pharmaceutical Industries - Key offerings
• Exhibit 73: Teva Pharmaceutical Industries overview
• Exhibit 74: Teva Pharmaceutical Industries - Business segments
• Exhibit 75: Teva Pharmaceutical Industries - Organizational developments
• Exhibit 76: Teva Pharmaceutical Industries - Geographic focus
• Exhibit 77: Teva Pharmaceutical Industries - Segment focus
• Exhibit 78: Teva Pharmaceutical Industries - Key offerings

4